IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients

Table 1 Statistical analyses of the different IL28B genotypes and alleles in non-responder and sustained viral response patients n (%)

	Non-responders (NR = 79)	Responders (SVR = 87)	Odds ratio	95%CI	P value
CC (n = 24)	8 (33.3)	16 (66.7)	4.575	1.376-7.846	0.025
CT (n = 117)	58 (49.6)	59 (50.4)	0.858	0.538-1.449	0.589
TT (n = 25)	13 (52)	12 (48)	0.978	0.758-1.759	0.464
C (n = 165)	74 (44.8)	91 (55.2)	1.636	0.773-3.465	0.198
T (n = 167)	84 (50.3)	83 (49.7)	0.798	0.598-1.349	0.604

Frequencies of genotypes and alleles at IL28B SNP were compared between SVR and NR patients. Genotype CC were associated with SVR (P = 0.025). SVR: Sustained viral response; NR: Non-responder.

Table 2 Influence of cytomegalovirus infection on response rate to interferon combined therapy in chronic hepatitis C virus infected patients with IL28B CT genotype n (%)

HCV response to treatment (n =117)	IL 28B genotype (CT) +ve CMV patients (n = 45)	IL 28B genotype (CT) -ve CMV patients (n = 72)
NR (n = 59)	32 (71)	27 (38)
SVR (n = 58)	13 (29)	45 (62)

Reactivation of cytomegalovirus (CMV) was assessed by amplification of viral genome in all patients. Association of IL28B genotype CT and CMV emia with response to interferon based therapy is illustrated in this table. SVR: Sustained viral response; NR: Non-responder.